| || |
Dr Reddy received his Ph. D. degree in India. There he published his Ph.D. work as back to back papers in the prestigious journal Nature. He received the National Young Scientist award for his work. Later he received his postdoctoral training at Yale University. He joined as a scientist at NCI-Frederick where he identified erg-1 and erg-2 genes (in collaboration with Dr Veena Rao) which are shown to be involved in the majority of prostate cancers and also shown to be responsible for Ewing sarcoma and certain leukemias (AML). In addition, Dr Reddy and Rao identified several genes/gene functions which include C-ets-1, human Fli-1, ELK-1, EWS-Fli-1, EWSb, EWS-erg, TLS/FUS, TLS/FUS-erg, Brca2a, EWS-ATF-1, Brca1a and 1b involved in a wide variety of cancers. Dr Reddy's work revealed that aberrant fusion proteins target transcriptional co-factors and this may be in part responsible for cancer. Based on the function of these oncoproteins, Dr Reddy developed a cell based assay and identified several small molecule therapeutic agents that target only cancer cells but not normal cells. These novel drugs can be used as targeted therapeutic agents to prostate, breast, ovarian and pancreatic cancers (patent pending). Dr Reddy received several RO1, ACS and DOD grants to carryout this work. Dr Reddy received several personal awards that include GCC Distinguished Cancer Scholar award, ATA award for Excellence in Science, Dean's recognition award for Research, Morehouse School of Medicine and Swebelius Cancer Research Award of Yale University. Dr Reddy is currently working as Professor and co-Director, Cancer Biology Program, Dept. of OB/GYN, Morehouse School of Medicine. Previous positions include Assistant Professor at Wistar Institute, Associate Professor at Temple and Thomas Jefferson University, and Professor and Director, Division of Cancer Genetics, MCP Hahnemann University and Drexel University, Philadelphia.